SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
KRX:302440
Price:
52 500
KRW
-5.41%
Market Closed
Market Cap:
4.1T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
SK Bioscience Co Ltd
52500
-3000 (-5.41%)
| 52 Week Range |
44 700
73 300
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
SK Bioscience Co Ltd
Income Statement
Earnings Waterfall
SK Bioscience Co Ltd
SK Bioscience Co Ltd
|
Revenue
|
201.3B
KRW
|
|
Cost of Revenue
|
-146.5B
KRW
|
|
Gross Profit
|
54.8B
KRW
|
|
Operating Expenses
|
-152B
KRW
|
|
Operating Income
|
-97.2B
KRW
|
|
Other Expenses
|
54B
KRW
|
|
Net Income
|
-43.3B
KRW
|
Income Statement
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Currency: KRW
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Revenue |
223 385
N/A
|
225 611
+1%
|
338 321
+50%
|
423 012
+25%
|
545 152
+29%
|
929 001
+70%
|
903 382
-3%
|
897 059
-1%
|
767 283
-14%
|
456 726
-40%
|
390 231
-15%
|
278 429
-29%
|
419 202
+51%
|
369 506
-12%
|
371 179
+0%
|
371 479
+0%
|
201 300
-46%
|
|
| Gross Profit | ||||||||||||||||||
| Cost of Revenue |
(128 874)
|
(130 269)
|
(169 577)
|
(184 162)
|
(226 643)
|
(358 718)
|
(358 693)
|
(349 263)
|
(295 051)
|
(217 115)
|
(197 543)
|
(165 406)
|
(256 486)
|
(227 263)
|
(224 425)
|
(213 071)
|
(146 547)
|
|
| Gross Profit |
94 511
N/A
|
95 342
+1%
|
168 744
+77%
|
238 850
+42%
|
318 509
+33%
|
570 283
+79%
|
544 689
-4%
|
547 796
+1%
|
472 232
-14%
|
239 611
-49%
|
192 688
-20%
|
113 023
-41%
|
162 716
+44%
|
142 243
-13%
|
146 754
+3%
|
158 408
+8%
|
54 753
-65%
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(53 519)
|
(57 631)
|
(77 318)
|
(71 595)
|
(87 321)
|
(96 063)
|
(100 432)
|
(108 505)
|
(111 988)
|
(124 597)
|
(130 615)
|
(147 449)
|
(157 563)
|
(154 231)
|
(158 809)
|
(155 093)
|
(151 989)
|
|
| Selling, General & Administrative |
(28 079)
|
(30 286)
|
(40 409)
|
(36 701)
|
(43 030)
|
(46 656)
|
(47 511)
|
(51 723)
|
(52 944)
|
(62 773)
|
(64 522)
|
(65 823)
|
(67 957)
|
(62 648)
|
(64 467)
|
(65 429)
|
(68 270)
|
|
| Research & Development |
(24 227)
|
(24 645)
|
(35 138)
|
(33 275)
|
(42 391)
|
(47 250)
|
(50 418)
|
(53 803)
|
(55 621)
|
(57 960)
|
(61 780)
|
(76 951)
|
(84 389)
|
(85 743)
|
(86 878)
|
(81 769)
|
(75 545)
|
|
| Depreciation & Amortization |
(1 211)
|
(2 701)
|
(1 779)
|
(1 628)
|
(1 908)
|
(2 157)
|
(2 503)
|
(2 978)
|
(3 423)
|
(3 865)
|
(4 313)
|
(4 675)
|
(5 217)
|
(5 839)
|
(6 310)
|
(6 741)
|
(7 020)
|
|
| Other Operating Expenses |
0
|
0
|
9
|
9
|
9
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 154)
|
(1 154)
|
(1 154)
|
|
| Operating Income |
40 993
N/A
|
37 710
-8%
|
91 426
+142%
|
167 256
+83%
|
231 188
+38%
|
474 220
+105%
|
444 257
-6%
|
439 292
-1%
|
360 244
-18%
|
115 014
-68%
|
62 073
-46%
|
(34 426)
N/A
|
5 153
N/A
|
(11 988)
N/A
|
(12 055)
-1%
|
3 315
N/A
|
(97 236)
N/A
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
(2 685)
|
(2 251)
|
(997)
|
388
|
(3 591)
|
(5 401)
|
2 587
|
(1 791)
|
5 089
|
31 166
|
26 979
|
38 246
|
33 986
|
19 311
|
22 225
|
19 925
|
31 839
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 154)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(5)
|
236
|
254
|
19
|
21
|
24
|
(112)
|
(159)
|
(355)
|
(435)
|
(324)
|
(286)
|
(97)
|
(68)
|
(66)
|
(113)
|
(110)
|
|
| Total Other Income |
459
|
1 597
|
1 652
|
3 905
|
2 518
|
2 286
|
2 111
|
(1 047)
|
(2 080)
|
(4 012)
|
(5 416)
|
(4 802)
|
(4 862)
|
1 226
|
3 083
|
2 394
|
1 749
|
|
| Pre-Tax Income |
38 763
N/A
|
37 293
-4%
|
92 335
+148%
|
171 567
+86%
|
230 134
+34%
|
471 128
+105%
|
448 843
-5%
|
436 294
-3%
|
362 898
-17%
|
141 733
-61%
|
83 311
-41%
|
(1 267)
N/A
|
34 179
N/A
|
7 327
-79%
|
13 187
+80%
|
25 521
+94%
|
(63 759)
N/A
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
(5 035)
|
(4 404)
|
(17 520)
|
(34 744)
|
(49 082)
|
(115 989)
|
(107 822)
|
(101 959)
|
(84 222)
|
(19 281)
|
(2 933)
|
19 543
|
11 710
|
14 990
|
9 681
|
1 914
|
20 484
|
|
| Income from Continuing Operations |
33 728
|
32 890
|
74 815
|
136 823
|
181 052
|
355 139
|
341 021
|
334 335
|
278 676
|
122 452
|
80 378
|
18 276
|
45 890
|
22 318
|
22 868
|
27 435
|
(43 274)
|
|
| Net Income (Common) |
33 728
N/A
|
32 890
-2%
|
74 815
+127%
|
136 823
+83%
|
181 052
+32%
|
355 139
+96%
|
341 021
-4%
|
334 335
-2%
|
278 676
-17%
|
122 452
-56%
|
80 378
-34%
|
18 276
-77%
|
45 890
+151%
|
22 318
-51%
|
22 868
+2%
|
27 435
+20%
|
(43 274)
N/A
|
|
| EPS (Diluted) |
552.91
N/A
|
530.48
-4%
|
1 168.97
+120%
|
1 782.44
+52%
|
2 392.32
+34%
|
4 810.09
+101%
|
4 427.83
-8%
|
4 341.73
-2%
|
3 618.08
-17%
|
1 589.84
-56%
|
1 046.8
-34%
|
238.01
-77%
|
597.42
+151%
|
289.79
-51%
|
297.64
+3%
|
357.09
+20%
|
-563.26
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
